{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:20:09Z","timestamp":1781104809463,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,8]]},"DOI":"10.7759\/cureus.41566","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T15:58:32Z","timestamp":1688831912000},"source":"Crossref","is-referenced-by-count":3,"title":["Effects of Angiotensin Receptor-Neprilysin Inhibitors Versus Enalapril or Valsartan on Patients With Heart Failure: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Arpit","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shourya","family":"Meyur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovish","family":"Wadhwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamaldeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishita","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giustino","family":"Varrassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese G","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023, 118:3272-87. 10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac248","article-title":"An update on global epidemiology in heart failure","volume":"43","author":"Becher PM","year":"2022","unstructured":"Becher PM, Lund LH, Coats AJ, Savarese G. An update on global epidemiology in heart failure. Eur Heart J. 2022, 43:3005-7. 10.1093\/eurheartj\/ehac248","journal-title":"Eur Heart J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13672","article-title":"Angiotensin receptor-neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction","volume":"49","author":"Zhang Y","year":"2022","unstructured":"Zhang Y, Yuan M, Suo Y, et al.. Angiotensin receptor-neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction. Clin Exp Pharmacol Physiol. 2022, 49:848-57. 10.1111\/1440-1681.13672","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113701","article-title":"Progress and prospects of Sacubitril\/Valsartan: based on heart failure with preserved ejection fraction","volume":"155","author":"Jia R","year":"2022","unstructured":"Jia R, Ji Y, Sun D. Progress and prospects of Sacubitril\/Valsartan: based on heart failure with preserved ejection fraction. Biomed Pharmacother. 2022, 155:113701. 10.1016\/j.biopha.2022.113701","journal-title":"Biomed Pharmacother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175053","article-title":"Effect of sacubitril\/valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: a real-world 12-week study","volume":"928","author":"Jia R","year":"2022","unstructured":"Jia R, Zhang X, Xu Y, et al.. Effect of sacubitril\/valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: a real-world 12-week study. Eur J Pharmacol. 2022, 928:175053. 10.1016\/j.ejphar.2022.175053","journal-title":"Eur J Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263131","article-title":"Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Liu X","year":"2022","unstructured":"Liu X, Liu H, Wang L, Zhang L, Xu Q. Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2022, 17:e0263131. 10.1371\/journal.pone.0263131","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins JP","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al.. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011, 343:d5928. 10.1136\/bmj.d5928","journal-title":"BMJ"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JP","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003, 327:557-60. 10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez EJ","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al.. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019, 380:539-48. 10.1056\/NEJMoa1812851","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.844","article-title":"Benefits and adverse effects of sacubitril\/valsartan in patients with chronic heart failure: a systematic review and meta-analysis","volume":"9","author":"Charuel E","year":"2021","unstructured":"Charuel E, Menini T, Bedhomme S, et al.. Benefits and adverse effects of sacubitril\/valsartan in patients with chronic heart failure: a systematic review and meta-analysis. Pharmacol Res Perspect. 2021, 9:e00844. 10.1002\/prp2.844","journal-title":"Pharmacol Res Perspect"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon SD","year":"2019","unstructured":"Solomon SD, McMurray JJ, Anand IS, et al.. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019, 381:1609-20. 10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon SD","year":"2012","unstructured":"Solomon SD, Zile M, Pieske B, et al.. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012, 380:1387-95. 10.1016\/s0140-6736(12)61227-6","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2021.4567","article-title":"Effect of treatment with Sacubitril\/Valsartan in patients with advanced heart failure and reduced ejection fraction","volume":"7","author":"Mann DL","year":"2022","unstructured":"Mann DL, Givertz MM, Vader JM, et al.. Effect of treatment with Sacubitril\/Valsartan in patients with advanced heart failure and reduced ejection fraction. JAMA Cardiol. 2022, 7:17-25. 10.1001\/jamacardio.2021.4567","journal-title":"JAMA Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2076","article-title":"OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction","volume":"23","author":"Piepoli MF","year":"2021","unstructured":"Piepoli MF, Hussain RI, Comin-Colet J, Dosantos R, Ferber P, Jaarsma T, Edelmann F. OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction. Eur J Heart Fail. 2021, 23:127-35. 10.1002\/ejhf.2076","journal-title":"Eur J Heart Fail"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-0854","article-title":"Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction - results from the parallel-HF study","volume":"85","author":"Tsutsui H","year":"2021","unstructured":"Tsutsui H, Momomura SI, Saito Y, et al.. Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction - results from the parallel-HF study. Circ J. 2021, 85:584-94. 10.1253\/circj.CJ-20-0854","journal-title":"Circ J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.06.073","article-title":"Angiotensin receptor-neprilysin inhibition based on history of heart failure and use of renin-angiotensin dystem Antagonists","volume":"76","author":"Ambrosy AP","year":"2020","unstructured":"Ambrosy AP, Braunwald E, Morrow DA, et al.. Angiotensin receptor-neprilysin inhibition based on history of heart failure and use of renin-angiotensin dystem Antagonists. J Am Coll Cardiol. 2020, 76:1034-48. 10.1016\/j.jacc.2020.06.073","journal-title":"J Am Coll Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.2822","article-title":"Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction","volume":"5","author":"Gaziano TA","year":"2020","unstructured":"Gaziano TA, Fonarow GC, Velazquez EJ, Morrow DA, Braunwald E, Solomon SD. Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction. JAMA Cardiol. 2020, 5:1236-44. 10.1001\/jamacardio.2020.2822","journal-title":"JAMA Cardiol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.788","article-title":"What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?","volume":"19","author":"Pellicori P","year":"2017","unstructured":"Pellicori P, Urbinati A, Shah P, et al.. What proportion of patients with chronic heart failure are eligible for sacubitril-valsartan?. Eur J Heart Fail. 2017, 19:768-78. 10.1002\/ejhf.788","journal-title":"Eur J Heart Fail"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2020.100486","article-title":"Sacubitril\/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: the Daunia Heart Failure Registry","volume":"27","author":"Correale M","year":"2020","unstructured":"Correale M, Mallardi A, Mazzeo P, et al.. Sacubitril\/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: the Daunia Heart Failure Registry. Int J Cardiol Heart Vasc. 2020, 27:100486. 10.1016\/j.ijcha.2020.100486","journal-title":"Int J Cardiol Heart Vasc"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12270","article-title":"Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design","volume":"5","author":"Jaffuel D","year":"2018","unstructured":"Jaffuel D, Molinari N, Berdague P, et al.. Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design. ESC Heart Fail. 2018, 5:222-30. 10.1002\/ehf2.12270","journal-title":"ESC Heart Fail"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1576481","article-title":"Sacubitril\/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction","volume":"35","author":"Cosentino ER","year":"2019","unstructured":"Cosentino ER, Degli Esposti D, Miceli R, et al.. Sacubitril\/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction. Curr Med Res Opin. 2019, 35:9-12. 10.1080\/03007995.2019.1576481","journal-title":"Curr Med Res Opin"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/2040622316665350","article-title":"Sacubitril\/valsartan in heart failure: latest evidence and place in therapy","volume":"7","author":"Kaplinsky E","year":"2016","unstructured":"Kaplinsky E. Sacubitril\/valsartan in heart failure: latest evidence and place in therapy. Ther Adv Chronic Dis. 2016, 7:278-90. 10.1177\/2040622316665350","journal-title":"Ther Adv Chronic Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101149","article-title":"Clinical outcomes of sacubitril\/valsartan in patients with acute heart failure: a multi-institution study","volume":"41","author":"Chen DY","year":"2021","unstructured":"Chen DY, Chen CC, Tseng CN, et al.. Clinical outcomes of sacubitril\/valsartan in patients with acute heart failure: a multi-institution study. EClinicalMedicine. 2021, 41:101149. 10.1016\/j.eclinm.2021.101149","journal-title":"EClinicalMedicine"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2017.68813","article-title":"The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril\/valsartan","volume":"13","author":"Yandrapalli S","year":"2017","unstructured":"Yandrapalli S, Aronow WS, Mondal P, Chabbott DR. The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril\/valsartan. Arch Med Sci. 2017, 13:1207-16. 10.5114\/aoms.2017.68813","journal-title":"Arch Med Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/170039-effects-of-angiotensin-receptor-neprilysin-inhibitors-versus-enalapril-or-valsartan-on-patients-with-heart-failure-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:42Z","timestamp":1707508962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/170039-effects-of-angiotensin-receptor-neprilysin-inhibitors-versus-enalapril-or-valsartan-on-patients-with-heart-failure-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,8]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.41566","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,8]]}}}